Articles from Yaqrit

LONDON, May 14, 2025 (GLOBE NEWSWIRE) -- Yaqrit, a late clinical-stage company developing life-saving treatments for advanced liver diseases, announced today the appointment of healthcare innovator and hedge fund strategist Ronen Israel to its management board. With a background in economics/finance and biomedical science, Ronen is a founder of disruptive oncology company BioConvergent Health and was a quantitative hedge fund manager for over twenty-five years. Separately, Yaqrit has appointed liver disease specialist Amrik Shah as Chief Biometrics Officer.

LONDON, May 07, 2025 (GLOBE NEWSWIRE) -- Yaqrit, a late clinical-stage company developing life-saving treatments for advanced liver diseases, is this week revealing data on the progress of both its phase 3 and phase 2b/3 candidate drugs – YAQ006 (IV) and YAQ007 (oral) - for hepatic encephalopathy (HE) at the forthcoming European Association for the Study of the Liver (EASL) Congress, Amsterdam May 7-10th in advance of its clinical trials. Collectively, the data provide an enhanced understanding of the mechanism of action, determine treatment-initiation and endpoints within the HE patient population and define the dosage of YAQ007 (the oral formulation of the ammonia scavenger) to be used for the prevention of recurrence of overt HE.

LONDON, April 28, 2025 (GLOBE NEWSWIRE) -- Yaqrit, a late clinical-stage company developing life-saving treatments for advanced liver diseases, announced today that it will share progress with investors, clinical and scientific peers at the forthcoming European Association for the Study of the Liver (EASL) Congress, Amsterdam, May 7-10th. Across eight presentations, Yaqrit researchers and collaborators demonstrate the rigorous approach taken in preparation for its upcoming advanced clinical trials:

LONDON, March 21, 2025 (GLOBE NEWSWIRE) -- Yaqrit, a late clinical-stage company developing life-saving treatments for advanced liver diseases, announced today a major £2.2 million ($2.85 million) clinical research grant that will fund the development of its extracorporeal liver support device, DIALIVE (YAQ002) for advanced liver disease patients and move the device closer to UKCA and CE mark for marketing authorization. The device treats patients with Acute-on-Chronic Liver Failure (ACLF) grade 2 and 3, a life-threatening condition affecting patients with cirrhosis characterized by multiorgan failure and high risk of mortality.

LONDON, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Yaqrit, a late clinical-stage clinical company developing lifesaving treatments for advanced liver diseases, announced today the appointment of a series of key senior board and management team positions as part of the implementation of its clinical development and commercialization strategy.

LONDON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Yaqrit, a late clinical-stage company developing life-saving treatments for advanced liver disease, announced today that its recently acquired ammonia scavenger, L-ornithine phenylacetate (OPA), is progressing to phase 3 for treatment of acute hepatic encephalopathy, a life-threatening complication of decompensated cirrhosis. Development will be via Yaqrit’s newly formed subsidiary Amalive Limited, named to reflect the profound impact of ammonia levels in the lives of patients with advanced liver disease.

LONDON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Yaqrit, a late-stage biotech and medtech company developing lifesaving treatments for advanced liver diseases, announced today that Troels Jordansen has joined Yaqrit as Chief Executive Officer. The company is preparing several late-stage trials of its products for the treatment of complications associated with advanced liver disease and preparing to launch a phase 3 study.